Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2014. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) related to the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding internal plan allocations rather than a financial performance report.
Material Changes
The filing details a revaluation of the cash element within the GSK 401K plan, which is notionally held in GSK American Depositary Shares (ADSs). On February 14, 2014, at a price of $55.89 per ADS, the following increases in notional ADS allocations occurred:
- Dr M M Slaoui (Director/PDMR): Increase of 14 ADSs.
- Dr K Slaoui (Connected Person): Increase of 3 ADSs.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Investor Verification Checklist
- Verify the impact of the 401K plan revaluation on total director holdings.
- Confirm the ADS price of $55.89 used for the February 14, 2014 allocation.
- Review the full annual report (Form 20-F) for comprehensive financial performance data not included in this 6-K.